Invesco Nasdaq Biotechnology ETF

Biogen and Stoke Therapeutics Report Positive Clinical Results for Dravet Syndrome Drug

Kevin Joseph Fitzgerald Sells Alnylam Pharmaceuticals Stock

Alirame Pharmaceuticals Enters into $1.23 Billion Agreement with Tenaya Therapeutics

Institutional Investors and Executives Reduce Gilead Sciences Holdings

Alnylam Pharmaceuticals Receives 'Modest Buy' Consensus Rating from Analysts

argenx SE Announces Positive Results from VYVGART's Phase III Clinical Trial

Paul A. Mahon Sells Shares of U.T. Company

Insmed CEO William Lewis Sells Common Stock

Vertex Pharmaceuticals Announces Positive Results from Phase 4 Study of JOURNAVX for Postoperative Pain Management

Biogen advances salanersen into SMA Phase 3 trials

South Africa Urges Local Production of HIV Prevention Drug Lenacapavir

Evercore ISI Maintains Hold Rating on Moderna, BofA Reiterates Sell

Dimensional Fund Advisors LP Increased Holdings in Amgen Inc.

CEO of United Therapeutics Sells Company's Common Stock

Moderna expects total available liquidity to reach $5.4B to $5.9B by the end of 2026

Moderna's Combo COVID-Flu Vaccine mCombriax Ready for EMA Approval

Amgen Exec Esteban Santos Sells Company Stock

Judy D. Olian Sold Shares of United Therapeutics

Alirium Pharmaceuticals Receives Positive Recommendation for AMVUTTRA Public Reimbursement from Canadian Health Authority

United Therapeutics' Hypertension Drug Trial Meets All Primary and Secondary Goals

Peraso

QUARTZSEA ACQUISITION CORP ORD USD0.0001 (18/02/2030) (S/R)

Decent

Edesa Biotech

Cre8 Enterprise - CL

AN2 Therapeutics

Day One Biopharmaceuticals

Epsium Enterprise

Silynxcom

Aptera Motors - B

LABD

ABBV

ARKG

SBIO

IBBQ

Gabelli Funds LLC has reduced its stake in AbbVie Inc. (NYSE:ABBV) by 6.2%, now holding 100,963 shares valued at $23.38 million. Other institutional investors have also adjusted their positions in AbbVie. Analysts have mixed ratings on the stock, with a consensus price target of $253.15. AbbVie recently reported earnings of $2.71 per share, exceeding estimates, and declared a quarterly dividend of $1.73 per share, yielding 3.0%. The stock is currently trading at $230.41, down 0.8%.

Market Beat

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bear 3X

Abbvie

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

iShares Biotechnology ETF

iShares US Pharma

ALPS Medical Breakthrough

VanEck Biotech ETF

VG Health

SPDR S&P Biotech

Gabelli Funds LLC Decreases Stake in AbbVie Inc. $ABBV

Gamco Investors INC. ET AL reduced its stake in Pfizer Inc. by 16.1% in Q3, selling 107,937 shares, leaving them with 563,304 shares valued at $14.35 million. Other institutional investors, including Vanguard and Geode Capital, also adjusted their holdings. Positive developments for Pfizer include the approval of its GLP-1 weight-management drug in China and upgrades from analysts, while challenges such as declining COVID revenues and competition remain.

- Gamco Investors INC. ET AL decreased its stake in Pfizer Inc. by 16.1%, now holding 563,304 shares worth approximately $14.35 million.  
- Institutional investors, including Vanguard Group Inc. and Geode Capital Management LLC, have increased their positions, indicating significant interest in Pfizer shares, which are currently dominated by hedge funds.  
- Recent developments include positive market responses to Pfizer’s GLP-1 weight management drug approval in China, while there are concerns about potential declines in COVID-related revenues and other market risks.

iShares Global Healthcare

Pfizer

Direxion Daily Biotech Top 5 Bull 2X ETF

Gamco Investors INC. ET AL Sells 107,937 Shares of Pfizer Inc. $PFE

CGON

CG Oncology (NASDAQ:CGON) executives presented promising clinical results for their investigational therapy, Credo, at a recent conference. The BOND-003 trial's Cohort C reported a 75.5% complete response rate in over 110 patients with BCG-unresponsive carcinoma in situ. The company plans to file for FDA approval in 2026, highlighting Credo's potential for durable responses and ease of administration in urology practices. Additional studies are ongoing, including trials for papillary disease and BCG-naive patients, with encouraging early results reported.

CG oncology

CG Oncology Conference: Credo Posts 75.5% CR in BOND-003, BLA Filing Targeted for 2026

CAPR

Capricor Therapeutics (CAPR) faces increased scrutiny as the FDA tightens its expedited approval pathway, impacting its Duchenne muscular dystrophy program. The company's share price recently rose to $27.90, with a one-year total shareholder return of 117.80%. Analysts suggest a fair value of $50.80, indicating potential upside. The narrative emphasizes the growing demand for rare disease treatments and Capricor's innovative exosome platform, which could drive future revenue growth. However, success hinges on meeting FDA expectations and managing R&D costs effectively.

Simplywall

Capricor Therap

A Look At Capricor Therapeutics (CAPR) Valuation As FDA Tightens Expedited Approval Pathway

CPIX

Cipla USA, Inc, a subsidiary of Cipla, is recalling over 400 cartons of Nilotinib Capsules (150 mg and 200 mg) due to manufacturing issues, as reported by the USFDA. The Class III voluntary recall, initiated on February 18, indicates that exposure to the product is not likely to cause adverse health consequences. Nilotinib is used to block cancer cell multiplication. Indian pharmaceutical companies play a significant role in supplying medications to the US market, with a substantial share of prescriptions filled by them in 2022.

Business Standard

Cumberland Pharma

Citius Pharma

Cipla's US unit recalls 400+ cartons of generic anti-cancer drug: USFDA

STOK

Biogen and Stoke Therapeutics reported positive clinical results for zorevunersen in Dravet syndrome, indicating potential as a disease-modifying therapy. Biogen also shared new data on SPINRAZA for spinal muscular atrophy (SMA) and advanced salanersen into Phase 3 trials. These developments enhance Biogen's position in neurology and rare diseases, with a focus on high unmet needs. Investors should monitor upcoming regulatory milestones and the company's ability to convert late-stage assets into successful products amidst competition. Analysts highlight both risks and potential rewards related to Biogen's evolving pipeline.

Stoke Therapeutics

Biogen

Biogen’s Dravet And SMA Advances Add Depth To Long Term Story

Codexis CEO Alison Moore highlighted the company's focus on RNA medicines manufacturing at the TD Cowen Health Care Conference, targeting significant growth by 2026 through its ECO Synthesis platform. The RNA medicines market is expanding, with Codexis addressing challenges in oligonucleotide production. The legacy biocatalysis business faces competition but supports Phase III assets. A supply assurance agreement with Merck enhances supply chain security, while Codexis engages with CDMOs for technology transfer and commercial licensing. The total addressable market for RNA medicines is estimated at $2 billion by 2030.

Codexi

Merck

Codexis Targets 2026 Inflection as CEO Touts ECO Synthesis Push in RNA Manufacturing at TD Cowen Conf

Wave Life Sciences Pte. Ltd (WVE) held its Q4 earnings call, highlighting a focus on strong clinical data despite a significant revenue drop due to the termination of its Takeda collaboration. The company reported a net loss of $53.2 million for the quarter and $204.4 million for the year. Promising interim data from its obesity candidate WVE-007 and RNA editing program WVE-006 were discussed, with plans for further trials and a cash runway projected to last until Q3 2028. The GSK partnership adds potential for future milestones, though uncertainties remain regarding long-term capital needs.

Tip Ranks

Wave Life Sciences

Bioshares Biotech Clinical Trials Fd

Takeda Pharmaceutical Company

Wave Life Sciences Bets on Data Over Near-Term Revenue

PILL

Bristol Myers Squibb has received FDA approval for its oral drug Sotyktu to treat adults with active psoriatic arthritis, expanding its immunology portfolio. The approval follows positive results from Phase 3 trials, showing significant disease control compared to placebo. Despite a slight after-hours stock dip, the company emphasizes Sotyktu's role in managing symptoms of psoriatic disease. The drug's safety profile is similar to previous studies, with common side effects including respiratory infections and mouth ulcers. This approval builds on its initial 2022 clearance for moderate-to-severe plaque psoriasis.

benzinga_article

Direxion Pharma & Medical Bull 3X

Bristol-Myers Squibb Company

Bristol Myers Squibb

Bristol Myers Wins FDA Approval for Sotyktu for Psoriatic Arthritis

ELIL

Eli Lilly, Day One Biopharmaceuticals, Pfizer, AbbVie, and Abbott Laboratories are highlighted as key pharmaceutical stocks to watch, according to MarketBeat. These companies are involved in developing and selling various drugs and therapies, with their stock performance influenced by drug pipelines and regulatory approvals. Eli Lilly focuses on diabetes and obesity treatments, while Day One targets genomically defined cancers. Pfizer offers a range of medicines, including COVID-19 treatments, AbbVie specializes in autoimmune and cancer therapies, and Abbott provides a variety of healthcare products. Investors are advised to monitor these stocks closely.

- The article highlights five pharmaceutical stocks to watch: Eli Lilly, Day One Biopharmaceuticals, Pfizer, AbbVie, and Abbott Laboratories, noted for their recent high trading volumes.  
- It details each company's contributions, such as Eli Lilly's diabetes and obesity drugs, Day One's targeted therapies for cancers, and Pfizer's diverse biopharmaceutical products, including COVID-19 treatments.  
- The piece emphasizes that these stocks are evaluated based on various factors like drug pipelines, regulatory approvals, and industry risks, providing insights for potential investors.

Direxion Daily LLY Bull 2X Shares

Defiance Daily Target 2X Long LLY ETF

Abbott Laboratories

Pharmaceutical Stocks To Research - March 7th

TNYA

Alnylam Pharmaceuticals (ALNY) has entered a research collaboration with Tenaya Therapeutics to explore up to 15 genetic targets for cardiovascular drugs, supported by an upfront payment and milestone framework. Despite a recent 30% decline in share price to $320.66, analysts suggest Alnylam is undervalued with a fair value estimate of $491.92. The company is expected to see revenue growth from its RNAi therapies and international expansion of AMVUTTRA. However, high P/E ratios raise valuation risks, prompting investors to weigh growth potential against current multiples.

Tenaya Therapeutics

Alnylam Pharma

Assessing Alnylam Pharmaceuticals (ALNY) Valuation After New Cardiovascular Partnership With Tenaya Therapeutics

OCGN

Maxim Group analyst Michael Okunewitch has reiterated a Buy rating on Ocugen (OCGN) with a price target of $8.00. Despite Okunewitch's average return of -4.4% and a 35.45% success rate, he focuses on the Healthcare sector. Additionally, Ocugen received a Buy rating from Noble Financial's Robert LeBoyer on March 5, while TipRanks recently issued a Hold rating on the stock.

Ocugen

Ocugen (OCGN) Receives a Buy from Maxim Group

C4 Therapeutics (NASDAQ: CCCC) presented at the TD Cowen Healthcare Conference, outlining plans for its lead myeloma drug, cemsidomide, aiming for accelerated approval. CEO Andrew Hirsch emphasized the company's focus on targeted protein degradation and a sustainable pipeline. C4's Phase I study showed a 36% overall response rate, with higher rates at increased doses. The company has initiated the MOMENTUM Phase II study and plans a combination study with elranatamab. They target a 12-month enrollment period and aim for a first NDA submission for cemsidomide by 2028.

C4 Therapeutics

C4 Therapeutics Maps Accelerated Approval Path for Myeloma Drug Cemsidomide at TD Cowen Conference

QURE

Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against uniQure N.V. (NASDAQ: QURE) on behalf of investors who purchased shares between September 24, 2025, and October 31, 2025. The lawsuit alleges material misstatements regarding the company's Huntington's disease gene therapy drug, AMT-130. Investors have until April 13, 2026, to seek lead plaintiff status. Following revelations about the FDA's concerns regarding the drug's approval process, uniQure's share price dropped over 49%.

prnewswire

Uniqure

11:45 ETKessler Topaz Meltzer & Check, LLP Filed a Securities Fraud Class Action Lawsuit Against uniQure N.V. (QURE); April 13, 2026, Lead Plaintiff Deadline

Eli Lilly is currently a leading player in the GLP-1 drug market with its successful products, Mounjaro and Zepbound. However, the stock is highly valued with a P/E ratio of 44, raising concerns about future growth amid competition and potential patent expirations. Analysts suggest that while Eli Lilly's current success is notable, the company's long-term prospects may be uncertain, and investors should consider other stocks that may offer better returns.

Invesco Nasdaq Biotechnology ETF(IBBQ.US)

Gabelli Funds LLC Decreases Stake in AbbVie Inc. $ABBV

Gamco Investors INC. ET AL Sells 107,937 Shares of Pfizer Inc. $PFE

CG Oncology Conference: Credo Posts 75.5% CR in BOND-003, BLA Filing Targeted for 2026

A Look At Capricor Therapeutics (CAPR) Valuation As FDA Tightens Expedited Approval Pathway

Cipla's US unit recalls 400+ cartons of generic anti-cancer drug: USFDA